Generic
Tirofiban Hydrochloride
1 brands available in the market
At a glance
Tirofiban Hydrochloride is a glycoprotein IIb/IIIa receptor antagonist used to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
Description
Tirofiban is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. When administered intravenously, it inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. Platelet aggregation inhibition is reversible following cessation of the infusion.
Indications
- Non-ST elevation acute coronary syndrome (NSTE-ACS)
Therapeutic class
Anti-platelet Drugs
Pharmacological class
Glycoprotein IIb/IIIa Receptor Antagonist
Pharmacology
Tirofiban binds to the GP IIb/IIIa receptor, blocking fibrinogen binding and preventing platelet aggregation. IV administration achieves >90% inhibition of platelet aggregation within 10 minutes, which is reversible upon discontinuation.
Mechanism of action
Prevents platelet aggregation by blocking GP IIb/IIIa receptors.
Dosage
Adult Dose (IV):
- 25 mcg/kg over 5 minutes, then 0.15 mcg/kg/min (or 0.075 mcg/kg/min if serum creatinine ≤60 mL/min), for up to 18 hours
Administration
- IV administration only
- Administered by a healthcare professional in a hospital
- Do not use if solution is not clear or seal is broken
- Do not administer through the same IV line as diazepam
Missed dose
If you miss a dose, consult your doctor.
Side effects
Most Common Side Effect:
- Bleeding
Precautions & warnings
- Bleeding risk: Minimize traumatic procedures (arterial and venous punctures, IM injections)
- Thrombocytopenia: Monitor platelet counts 6 hours after initiation and daily; discontinue tirofiban and heparin if <90,000/mm³
- Increased bleeding risk with fibrinolytics, anticoagulants, antiplatelets
Contraindications
- Severe hypersensitivity to tirofiban (anaphylaxis)
- History of thrombocytopenia following prior tirofiban exposure
- Active internal bleeding or bleeding diathesis
- Major surgical procedure or severe physical trauma within the previous month
Drug interactions
- Antiplatelets, thrombolytics, heparin, aspirin: Increased bleeding risk
Food interactions
Alcohol consumption is not relevant (injection).
Use in pregnancy
Use in Pregnancy: No fetal harm in animal studies; adequate human data not available; use only if clearly needed; consult your doctor.
Pregnancy Category: B — always consult a doctor before taking during pregnancy.
Use in lactation
Use in Lactation: Unknown if excreted in human milk; significant levels in rat milk; decide whether to discontinue nursing or the drug; consult your doctor.
Pediatric use
Safety and efficacy not established in pediatric patients
Geriatric use
Caution required in elderly patients
Renal / hepatic impairment
Renal Impairment: Infusion dose 0.075 mcg/kg/min if serum creatinine ≤60 mL/min; consult your doctor.
Hepatic Impairment: Caution required; consult your doctor.
Overdose effects
Overdose increases bleeding risk; provide symptomatic and supportive treatment.
Storage conditions
Store at 15-30°C; do not freeze; protect from light.
Chemical structure
Tirofiban Hydrochloride